NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza
pharmafile | October 1, 2018 | News story | Sales and Marketing | HIV, Janssen, NHS, Symtuza, pharma
Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its once-daily single tablet regimen of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), meaning affected individuals will be able to access the drug through regular clinician prescriptions across England.
The combination will be made available to adult and adolescent patients aged 12 years and older who weigh at least 40kg, and is the only single tablet regimen available in this patient population. These patients will be able to access the drug when:
- It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF fixed dose combination (FDC) utilised under the tenofovir-AF policy
- It is part of the Darunavir/cobicistat/emtricitabine/tenofovir-AF FDC, used outside the tenofovir-AF policy where there is a multidisciplinary team (MDT)-documented requirement for this regimen and it falls within regional prescribing guidelines
“We are delighted that NHSE has provided vital funding for this treatment option; enabling access for individuals who require a darunavir-based STR to effectively control their HIV, with the potential to support adherence to treatment,” says Jennifer Lee, Director of Health Economics, Market Access and Reimbursement (HEMAR) and Advocacy at Janssen. “This milestone reflects our efforts to help simplify the way in which HIV is treated, supporting people living with HIV to achieve an undetectable viral load while enjoying an improved quality of life. We are thankful for NHSE’s collaboration throughout this process.”
Matt Fellows
Related Content
A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …
The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …
Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …
